Patents Examined by Alana M. Harris
  • Tumor associated nucleic acids and uses therefor
    Patent number: 7001999
    Abstract: The invention describes SAGE (sdph3.10) and sdp3.5 tumor associated nucleic acids, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such nucleic acid molecules, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a sdph3.10 and/or sdp3.5 gene product.
    Type: Grant
    Filed: October 30, 1998
    Date of Patent: February 21, 2006
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Valerie Martelange, Charles De Smet, Thierry Boon-Falleur
  • Time-staggered utilization of tumor cells in combination with intact antibodies for immunization
    Patent number: 6994853
    Abstract: The invention relates to the time-staggered utilization of tumor cells in combination with intact, preferably heterologous antibodies for the immunization of humans and animals.
    Type: Grant
    Filed: September 22, 1999
    Date of Patent: February 7, 2006
    Assignee: Trion Pharma GmbH
    Inventors: Horst Lindhofer, Peter Ruf
  • Reovirus clearance of ras-mediated neoplastic cells from mixed cellular compositions
    Patent number: 6994858
    Abstract: Reovirus can be used to selectively remove ras-mediated neoplastic cells from a cellular composition. It is of particular interest to purge autographs which may contain neoplastic cells with reovirus before transplanting the autographs back into the recipient, thereby reducing the risk of introducing or reintroducing neoplastic cells into the recipient.
    Type: Grant
    Filed: May 3, 2001
    Date of Patent: February 7, 2006
    Assignee: Oncolytics Biotech Inc.
    Inventors: Donald Morris, Bradley G. Thompson, Matthew C. Coffey
  • Ganglioside-KLH conjugate vaccines plus QS-21
    Patent number: 6967022
    Abstract: This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of ganglioside or oligosaccharide portion thereof conjugated to an immunogenic protein effective to stimulate or enhance antibody production in the subject, an effective amount of adjuvant and a pharmaceutically acceptable vehicle.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 22, 2005
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Philip Ordway Livingston, Friedhelm Helling
  • Method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancer
    Patent number: 6953658
    Abstract: The present invention provides new methods and agents for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating gastrointestinal cancer.
    Type: Grant
    Filed: March 9, 2001
    Date of Patent: October 11, 2005
    Assignee: diaDexus, Inc.
    Inventors: Roberto A. Macina, Alejandra Piderit, Yongmng Sun
  • Fas antigen derivative
    Patent number: 6953847
    Abstract: This invention provides a novel Fas antigen derivative which comprises at least a part or entire portion of Fas antigen extracellular region polypeptide in which at least one amino acid residue is deleted from a group of amino acid residues starting from the N-terminal amino acid residue of the Fas antigen polypeptide to a cysteine residue most close to the N-terminal side (excluding said cysteine residue), as well as a DNA fragment which encodes said Fas antigen derivative, a recombinant DNA molecule which contains said DNA sequence, a transformant in which said recombinant DNA molecule is introduced, a method for the production of said Fas antigen derivative, a medicament which contains said novel Fas antigen derivative as the active ingredient and a method for the improvement of activities and functions of Fas antigen and the like.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: October 11, 2005
    Assignees: Mochida Pharmaceutical Co., Ltd., Osaka Bioscience Institute
    Inventors: Norio Nakamura, Shigekazu Nagata
  • Fas ligand derivative
    Patent number: 6951919
    Abstract: This invention provides a soluble Fas ligand which functions as a Fas antagonist or an apoptosis regulator, a novel Fas ligand derivative which has excellent apoptosis-inducing activity and cytotoxic activity, and a DNA encoding such peptide.
    Type: Grant
    Filed: September 17, 1998
    Date of Patent: October 4, 2005
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Shigekazu Nagata, Masato Tanaka
  • Method of diagnosing, monitoring, and staging colon cancer
    Patent number: 6949339
    Abstract: The present invention provides a new method for detecting, diagnosing, monitoring, staging, and prognosticating colon cancer.
    Type: Grant
    Filed: May 12, 1999
    Date of Patent: September 27, 2005
    Assignee: diaDexus, Inc.
    Inventors: Roberto A. Macina, Fei Yang, Yongming Sun
  • Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
    Patent number: 6949245
    Abstract: The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.
    Type: Grant
    Filed: June 23, 2000
    Date of Patent: September 27, 2005
    Assignee: Genentech, Inc.
    Inventor: Mark Sliwkowski
  • Compositions and methods for treating cells having double minute DNA
    Patent number: 6946259
    Abstract: This invention provides methods by which test substances can be screened for their ability to inhibit, enhance or eliminate double minute (DM) or extrachromosomal DNA by micronucleation in cells. This invention also provides a method for inducing maturation or death of a cell having the capacity to generate micronuclei. It also provides a method of treating a disease in a subject, the cells correlated with the disease having DM and extrachromosomal DNA as well as the capacity to generate micronuclei to capture them. Further provided is a method of detecting chromosomal and extrachromosomal DNA in a cell.
    Type: Grant
    Filed: January 12, 1999
    Date of Patent: September 20, 2005
    Assignee: The Salk Institute For Biological Studies
    Inventors: Geoffrey M. Wahl, Noriaki Shimizu, Teru Kanda, H. Michael Shepard
  • Immunoassays for determining vitamin b12, and reagents and kits therefor
    Patent number: 6942977
    Abstract: Methods are described for the development of monoclonal antibodies to intrinsic factor and the application of said antibodies in the development of B12 immunoassays. In particular, antibodies are described that are capable of binding to intrinsic factor only in the absence of vitamin B12, and that are released from binding in the presence, and upon the binding, of vitamin B12 to intrinsic factor. Assays may be formatted such that either antibody or intrinsic factor is immobilized or labeled.
    Type: Grant
    Filed: May 28, 1993
    Date of Patent: September 13, 2005
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Karel Newman, Jane Schmidt, Paul Wegfahrt
  • Transmembrane protein expressed in prostate cancer
    Patent number: 6943235
    Abstract: A novel prostate tumor associated gene (designated 24P4C12) and its encoded protein is described. 24PC12 is highly expressed in prostate tissue xenografts, providing evidence that it is turned on in at least some prostate cancers. 24P4C12 provides a diagnostic and/or therapeutic target for prostate and other cancers.
    Type: Grant
    Filed: April 12, 2000
    Date of Patent: September 13, 2005
    Assignee: Agensys, Inc.
    Inventors: Daniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran
  • Ganglioside-KLH conjugate vaccines plus QS-21
    Patent number: 6936253
    Abstract: This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of ganglioside or oligosaccharide portion thereof conjugated to an immunogenic protein effective to stimulate or enhance antibody production in the subject, an effective amount of adjuvant and a pharmaceutically acceptable vehicle.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 30, 2005
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Philip Ordway Livingston, Friedhelm Helling
  • Materials and methods for detection and treatment of breast cancer
    Patent number: 6936424
    Abstract: The invention provides a wide range of methods and compositions for detecting and treating breast cancer in an individual. Specifically, the invention provides target breast cancer-associated proteins, which permit a rapid detection, preferably before metastases occur, of breast cancer. The target breast cancer-associated protein may be detected, for example, by reacting the sample with a labeled binding moiety, for example, a labeled antibody capable of binding specifically to the protein. The invention also provides kits useful in the detection of breast cancer in an individual. In addition, the invention provides methods utilizing the breast cancer-associated proteins either as targets for treating breast cancer or as indicators for monitoring the efficacy of such a treatment.
    Type: Grant
    Filed: November 10, 2000
    Date of Patent: August 30, 2005
    Assignee: Matritech, Inc.
    Inventors: Brynmor Watkins, Robert P. Szaro
  • Melanoma therapy
    Patent number: 6923966
    Abstract: Methods for treating treatment-naive as well as treatment-experienced patients having melanoma to increase the progression-free survival time involving administering a therapeutically effective amount of pegylated interferon-alpha, e.g., preferably pegylated interferon alpha-2b, as adjuvant therapy to definitive surgery are disclosed.
    Type: Grant
    Filed: July 12, 2001
    Date of Patent: August 2, 2005
    Assignee: Schering Corporation
    Inventors: Mary Ellen Rybak, Esther Helen Rose
  • Nucleic acids encoding osteoprotegern-like proteins and methods of using same
    Patent number: 6916907
    Abstract: Disclosed are osteoprotegerin-like polypeptides, nucleic acids encoding osteoprotegerin-like polypeptides, and methods of using these molecules. The osteoprotegerin-like polypeptides sequence homology to osteoprotegerin and tumor necrosis factor receptor molecules.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: July 12, 2005
    Assignee: CuraGen Corporation
    Inventors: Meijia Yang, Henri Lichenstein, William F. McDonald, Richard A. Shimkets
  • Ganglioslide-KLH conjugate vaccine plus QS-21
    Patent number: 6916476
    Abstract: This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of ganglioside or oligosaccharide portion thereof conjugated to an immunogenic protein effective to stimulate or enhance antibody production in the subject, an effective amount of adjuvant and a pharmaceutically acceptable vehicle.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 12, 2005
    Assignee: Sloan-Kettering Institute for Cancer Institute
    Inventors: Philip Ordway Livingston, Friedhelm Helling
  • Medical uses of scuPA/suPAR complex
    Patent number: 6911316
    Abstract: Methods of using a complex (scuPA/suPAR) which has thrombolytic activity under physiological conditions and in the presence of IgG, or of at least one IgG-derived peptide, which complex comprises a single chain urokinase type plasminogen activator (scuPA) and a soluble urokinase plasminogen activator receptor (suPAR), for the treatment and/or prevention of thromboembolic disorders associated with the formation of fibrin clots are disclosed.
    Type: Grant
    Filed: June 4, 1999
    Date of Patent: June 28, 2005
    Assignee: Thrombotech Ltd.
    Inventor: Abd Al-Roof Higazi
  • Compounds that inhibit the interaction between signal-transducing proteins and the GLGF (PDZ/DHR) domain and uses thereof
    Patent number: 6911526
    Abstract: This invention provides for a composition capable of inhibiting specific binding between a signal-transducing protein and a cytoplasmic protein. This invention also provides a method of identifying a compound capable of inhibiting specific binding between a signal-transducing protein and a cytoplasmic protein. This invention also provides a method of inhibiting the proliferation of cancer cells. This invention also provides a method of treating cancer with a composition in an amount effective to result in an amount in apoptosis of the cells. This invention also provides a method of inhibiting the proliferation of virally infected cells. This invention also provides for a method of treating a virally-infected subject with a composition in an amount effective to result in apoptosis of the cells. This invention also provides for pharmaceutical compositions.
    Type: Grant
    Filed: July 22, 1996
    Date of Patent: June 28, 2005
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Takaaki Sato, Junn Yanagisawa
  • Preventives and remedies for diffuse lung diseases
    Patent number: 6905684
    Abstract: Preventives and remedies for diffuse lung diseases whereby apoptosis can be inhibited and thus favorable preventive/therapeutic effects can be established. These drugs contain apoptosis-inhibiting substances as the active ingredient. The above apoptosis-inhibiting substances include Fas antagonists and Fas/Fas ligand binding inhibitors such as Fas derivatives and anti-Fas ligand antibodies.
    Type: Grant
    Filed: November 9, 1998
    Date of Patent: June 14, 2005
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kazuyoshi Kuwano